Harish G Ahuja
Overview
Explore the profile of Harish G Ahuja including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
30
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoang T, Campbell T, Zhang C, Kim K, Kolesar J, Oettel K, et al.
Invest New Drugs
. 2013 Jun;
32(1):195-9.
PMID: 23728919
Introduction: The primary objective of this phase II trial was to evaluate the efficacy and tolerability of vorinostat and bortezomib as third-line therapy in advanced non-small cell lung cancer (NSCLC)...
2.
Dooley W, Thropay J, Schreiber G, Puthawala M, Lane S, Wurzer J, et al.
Onco Targets Ther
. 2010 Nov;
3:197-203.
PMID: 21049086
Background: This retrospective, multicenter study evaluated the feasibility and safety of high-dose rate electronic brachytherapy (EBT) as a postsurgical adjuvant radiation therapy for endometrial cancer. Methods: Medical records were reviewed...
3.
Attia S, Traynor A, Kim K, Merchant J, Hoang T, Ahuja H, et al.
J Thorac Oncol
. 2008 Sep;
3(9):1018-25.
PMID: 18758305
Introduction: Exisulind is an apoptotic agent with preclinical activity in non-small cell lung cancer (NSCLC). Vinorelbine is safe and effective in older patients with advanced NSCLC. We assessed these agents...
4.
Hoang T, Kim K, Merchant J, Traynor A, McGovern J, Oettel K, et al.
J Thorac Oncol
. 2007 Apr;
1(3):218-25.
PMID: 17409860
Background: The study was designed to evaluate the safety and efficacy of exisulind, a selective apoptotic antineoplastic drug, in combination with gemcitabine as second-line therapy in patients with progressing advanced...